The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

AnaptysBio to Spin Off Biopharma Unit and Launches $100M Buyback Program

Key Facts

1AnaptysBio will spin off its biopharma operations into a new entity called First Tracks Biotherapeutics (TRAX) by April 20, 2026.

2CEO Daniel Faga sold 2,570 shares at approximately $57.91 each, but still retains 510,564 shares.

3The company announced a $100 million stock repurchase plan, and the new entity (TRAX) will launch with a $180 million cash balance.

Create Free Account

Version History

1 additional source confirmed this story

AnaptysBio (ANAB) has announced a strategic restructuring plan to spin off its biopharma operations into a new entity, First Tracks Biotherapeutics (TRAX). The spin-off is expected to be completed by April 20, 2026, with the new company launching with a robust cash balance of $180 million. Alongside the restructuring, AnaptysBio unveiled a $100 million share repurchase program aimed at enhancing shareholder value. In recent insider activity, CEO Daniel Faga sold 2,570 shares at an average price of $57.91, though he maintains a significant stake of over 510,000 shares. The move is designed to sharpen the company's focus on next-generation antibody therapeutics while optimizing capital allocation. Market analysts view the combination of the spin-off and buyback as a strategic effort to unlock value, despite the minor insider selling.